Stable engraftment, as well as graft versus host disease-free and relapse-free survival brought by the combination of CD7 targeted universal chimeric antigen receptor-T, and donor hemopoietic stem cells: Indication of a case report.
Shiqi LiZhongtao YuanLin LiuYu LiLe LuoLihui PengMengli XuPing YinYingnian ChenXiaoping LiQingying ZangXi ZhangSanbin WangPublished in: EJHaem (2024)
CD7 targeted CAR-T has demonstrated potential in the treatment of T cell malignancies but no study has been reported about its potential in the prophylaxis of GVHD in allo-HSCT. Here we reported a special case that a boy diagnosed with refractory acute T lymphoblastic leukemia (T-ALL) was treated with universal CD7 targeted CAR-T (CD7 UCAR-T) and parent-derived peripheral blood stem cells (PBSCs). Complete remission and full engraftment of donor was observed. In the later four months of follow-up, in the absence of any immunodepression treatment, no signs of GVHD were observed. This case initially demonstrates the potential of CD7 UCAR-T in the prophylaxis of GVHD.
Keyphrases
- nk cells
- stem cells
- free survival
- peripheral blood
- allogeneic hematopoietic stem cell transplantation
- liver failure
- bone marrow
- rheumatoid arthritis
- intensive care unit
- systemic lupus erythematosus
- hematopoietic stem cell
- cell therapy
- mesenchymal stem cells
- hepatitis b virus
- drug induced
- respiratory failure
- newly diagnosed
- aortic dissection
- smoking cessation